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Cardiovascular disease (CVD), principally heart disease and stroke, is the leading cause of death for both males and females in
developed countries. Aspirin is the most widely used and tested antiplatelet drug in CVD, and it is proven to be the cornerstone
of antiplatelet therapy in treatment and prevention of CVD in clinical trials in various populations. In acute coronary syndrome,
thrombotic stroke, and Kawasaki’s disease, acute use of aspirin can decrease mortality and recurrence of cardiovascular events. As
secondary prevention, aspirin is believed to be eﬀective in acute coronary syndrome, stable angina, revascularization, stroke, TIA,
and atrial ﬁbrillation. Aspirin may also be used for patients with a high risk of future CVD for primary prevention, but the balance
between beneﬁts and the possibility of side eﬀects must be considered.
1.Introduction
Cardiovascular disease (CVD) continues to be the leading
clinical and public health problem in developed countries
and increasingly so throughout the world. Heart disease and
stroke are the two main manifestations associated with CVD.
The World Health Organization estimates that CVD will be
the leading cause of death and disability worldwide by the
year 2020 [1].
Millions of patients worldwide take low-dose aspirin on
a daily basis for the treatment and prevention of CVD. By far,
aspirinisthemostwidelytestedantiplateletdruginrandom-
ized trials of treatment and prevention of CVD [2]. Despite
being one of the most widely used drugs in the 20th century,
the beneﬁts of aspirin in CVD have only relatively recently
been recognized. This paper aims to provide clinical practice
with a review of the evidence related to the use of aspirin for
the treatment and prevention of cardiovascular events.
2. Mechanismof Action
Aspirin’s mechanism of action involves inhibition of platelet
activation and aggregation, which was ﬁrst described in 1971
by British pharmacologist John Vane [3]. He demonstrated
that the main mechanism of action was the irreversible in-
hibition of the platelet-dependent enzyme cyclooxygenase
(COX), thereby preventing the synthesis of prostaglandins.
Subsequent researchers identiﬁed two COX isoenzymes,
COX-1 and COX-2 [4, 5]. In platelets, the COX-1 enzyme
produces thromboxane A2, a powerful promoter of platelet
aggregation. Thus, aspirin, by irreversibly inactivating COX-
1, thereby blocking the generation of thromboxane A2,
derives a potential antiplatelet eﬀect [6].
Platelet activation and aggregation with subsequent acti-
vation of the clotting cascade play critical roles in the onset
of acute occlusive vascular events, such as MI and occlusive
cerebrovascular accident (CVA) [7]. Because platelets do not
have nucleus and thus cannot regenerate COX, they become
an excellent target for antithrombotic therapy, while aspirin
shows both immediate and long-term eﬀects on platelets [8].
Other mechanisms of aspirin in CVD may also work.
Aspirin blocks the formation of COX-dependent vaso-
constrictors, which contribute to endothelial dysfunction
in atherosclerosis [9]. Thus, improvement of endothelial
dysfunction with aspirin may improve vasodilation, reduce
thrombosis, and inhibit progression of atherosclerosis. Fur-
thermore, aspirin reduces the inﬂammatory response in
patients with coronary artery disease [10] and may inhibit2 Thrombosis
the progression of atherosclerosis by protecting low-density
lipoprotein from oxidation [11].
3. Treatment inCardiovascularDisease
3.1. Therapy for Acute Coronary Syndrome. Convincing data
support the use of aspirin in the acute treatment of acute
coronary syndrome (ACS), including ST-elevation myocar-
dial infarction (STEMI), non-ST-elevation myocardial in-
farction (NSTEMI) and unstable angina pectoris (UA)
[12–14]. For ACS patients, the current American Heart
Association/American College of Cardiology (AHA/ACC)
guidelines recommend that aspirin should be administered
as soon as possible with an initial loading dose of 162–
325mg and continued indeﬁnitely with a dose of 75–162mg
daily [15, 16]. In the second International Study of Infarct
Survival (ISIS-2) study, the use of aspirin (162mg chewed, to
ensure rapid therapeutic blood levels) was associated with a
23% reduction of vascular mortality rate in MI patients and
close to a 50% reduction of nonfatal reinfarction or stroke,
w i t hb e n e ﬁ t ss e e ni nb o t hm e na n dw o m e n[ 12]. In UA and
USTEMI patients, aspirin has been shown to reduce the risk
offatalornonfatalMIby50–70%duringtheacutephaseand
by 50–60% at 3 months to 3 years [13, 14].
The highest beneﬁt of aspirin was seen in those undergo-
ing coronary angioplasty, with a 53% (P<0.0002) reduction
in MI, stroke, or vascular deaths [17]. In percutaneous
coronary intervention (PCI), the use of aspirin signiﬁcantly
reduces abrupt closure after balloon angioplasty and signiﬁ-
cantly reduces stent thrombosis rates [18].
3.2. Therapy for Kawasaki’s Disease. Kawasaki’s disease,
which is a kind of acute vasculitis, occurs most commonly
in children and in 15 to 25% of untreated cases results in
the development of coronary artery aneurysms [19]. In the
consensus guidelines from the Seventh American College
of Chest Physicians (ACCP) Conference on Antithrom-
botic and Thrombolytic Therapy, high-dose aspirin (80–
100mg/kg/day) is recommended during the acute phase of
the illness for its antiinﬂammatory eﬀects, followed by low-
dose aspirin (3–5mg/kg/day) for its antiplatelet eﬀect for
7 weeks or longer, maintaining it until the patient shows
no evidence of coronary changes. In children with coronary
aneurysms, long-term anticoagulation with warfarin and
low-dose aspirin is recommended [20].
3.3. Therapy for Thromboembolic Stroke. With regard to
stroke, the International Stroke Trial (IST) [21] and the
Chinese Acute Stroke Trial (CAST) [22] together enrolled
more than 40,000 patients admitted to hospital within
48 hours of the onset of stroke symptoms, who were
randomized within 48 hours of the onset of symptoms to
2 to 4 weeks of daily aspirin therapy (300mg and 160mg,
resp.)orplacebo.Resultsfrombothtrialssuggestthataspirin
therapy decreased the risk of recurrent stroke and death
without signiﬁcantly increasing the risk of hemorrhagic
stroke [21, 22]. These results are consistent with biochemical
evidence of episodic platelet activation during the ﬁrst 48h
after the onset of symptoms of an acute ischemic stroke and
with suppression of in vivo TXA2 biosynthesis in patients
receiving low-dose aspirin in this setting.
4.Secondary Prevention
Secondary prevention refers to the use of aspirin to prevent
cardiovascular and cerebrovascular events in patients who
have already experienced such an event or who have a high
riskofanevent.Long-termaspirintherapyreducestheyearly
risk of serious vascular events (nonfatal myocardial infarc-
tion, nonfatal stroke, or vascular death), which corresponds
to an absolute reduction of nonfatal events and to a smaller,
but still deﬁnite, reduction in vascular death. Against these
beneﬁts, the absolute increase in major gastrointestinal or
other major extracranial bleeds is relatively smaller. Hence,
for secondary prevention, the beneﬁts of aspirin therapy
substantially exceed the risks, and aspirin is recommended
as secondary prevention in conjunction with lifestyle change
and stopping smoking to reduce an individual’s overall risk
of further cardiovascular events.
The Antithrombotic Trialists’ (ATT) Collaboration per-
formed a meta-analysis in 2002, which examined 287 ran-
domized studies with 135000 high-risk patients in compar-
isons of antiplatelet therapy (predominantly aspirin) versus
control and 77000 in comparisons of diﬀerent antiplatelet
regimens [17]. The results showed that among these high-
risk patients, including acute MI, acute stroke, previous
stroke or transient ischemic attack (TIA), peripheral arterial
disease, atrial ﬁbrillation, antiplatelet therapy reduced the
combined outcome of any serious vascular event by about
25%, reduced nonfatal myocardial infarction by about 33%,
reduced nonfatal stroke by about 25%, and reduced vascular
mortality by about 17%. In each of the high-risk categories,
the absolute beneﬁts outweighed the absolute risks of major
extracranial bleeding.
Forthechoiceofaspirindosage,thisanalysisshowedthat
COX is virtually completely inhibited in platelets, producing
an antithrombotic eﬀect, within a few days of beginning
75mg aspirin daily. It was indicated that high doses of 500–
1500mg aspirin daily (which are more gastrotoxic48) were
no more eﬀective than medium doses of 160–325mg/day or
low doses of 75–150mg/day. Low-dose aspirin (75–150mg
daily) is an eﬀective antiplatelet regimen for long-term use,
and the eﬀects of doses lower than 75mg daily were less
certain. In clinical acute settings requiring an immediate
antithrombotic eﬀect (such as acute myocardial infarction,
acute ischaemic stroke, unstable angina), an initial loading
dose of about 150–300mg aspirin should probably be given
[17].
More recently, ATT Collaboration conducted another
meta-analysis involving 16 secondary prevention trials
(17000 individuals at high average risk, 43000 person-
years, 3306 serious vascular events) that compared long-
termaspirin versuscontrol.Thisanalysisshowedthataspirin
allocation yielded a greater absolute reduction in serious
vascular events (6.7% versus 8.2% per year, P<0.0001),
with a nonsigniﬁcant increase in haemorrhagic stroke but
reductions of about 20% in total stroke (2.08% versus 2.54%Thrombosis 3
per year, P = 0.002) and in coronary events (4.3% versus
5.3% per year, P<0.0001) [23].
Aspirin(oranotheroralantiplateletdrug)isprotectivein
most types of patient at increased risk of occlusive vascular
events, including those with an acute myocardial infarction
or ischaemic stroke, unstable or stable angina, previous
myocardial infarction, stroke or cerebral ischaemia, periph-
eral arterial disease, or atrial ﬁbrillation.
4.1.SecondaryPreventionforAcuteCoronarySyndromes. The
beneﬁt of aspirin therapy for preventing cardiovascular
events in patients with ACS (STEMI, USTEMI, UP) has been
deﬁnitively demonstrated in several trials [13, 14, 24, 25].
The previous meta-analysis by the ATT Collaboration [17]
reviewed 18788 patients with a history of MI from the 12
most important randomized clinical trials of aspirin and
showed that aspirin therapy reduced the relative risk of
nonfatal MI by 28% (P<0.0001), vascular death by 15%
(P<0.0006), and overall mortality by 11% (P = 0.02). The
daily dosage of 80–325mg appears to be eﬀective in reducing
the risk of cardiovascular events.
The 2007 ACC/AHA guidelines for the management of
patients with unstable angina and non-ST-segment elevation
MI recommend initiating daily aspirin therapy with at least
162mg as soon as possible after clinical presentation,
with 75–325mg daily indeﬁnitely thereafter [15]. The 2004
ACC/AHA guidelines for the management of patients with
ST-segment elevation MI are similar but recommend 75–
162mg daily as maintenance therapy after ST-segment
elevation MI. Aspirin therapy is considered a class I recom-
mendation (evidence supports that treatment is useful and
eﬀective) for all acute coronary syndromes [16]. The initial
dose of aspirin should be chewed and then swallowed during
acute coronary syndromes to attain a rapid onset of action.
4.2. Secondary Prevention for Chronic Stable Angina. As u b -
group analysis of the US Physicians’ Health Study (PHS) of
333 men with chronic stable angina indicated that aspirin
reduced the relative risk of acute MI by 87% (P<0.001)
[26]. The Swedish Angina Pectoris Aspirin Trial involved
2035 patients and found a 34% relative risk reduction in the
occurrence of a ﬁrst MI over a four-year follow-up period
in patients receiving 75mg of aspirin daily, compared with
patients receiving placebo [27].
The 2002 ACC/AHA guidelines for chronic stable angina
include a class IIa recommendation (the weight of evidence
where opinion is in favor of usefulness and eﬃcacy) for
prophylactic aspirin therapy to prevent MI and death [28].
4.3. Secondary Prevention for Revascularization. Aspirin has
been widely accepted as a cornerstone therapy in reducing
ischemic complications of coronary revascularization with
either coronary artery bypass graft surgery, balloon angio-
plasty, or stent implantation [29–31]. A number of studies
have demonstrated the eﬃcacy of aspirin in preventing
thrombosis, a common event following revascularization
[32–35].
Aspirin administered in the immediate postoperative
period following bypass surgery decreases the rate of graft
occlusion by approximately 50%, and continued therapy
leads to further decreases [29, 34]. Use of aspirin before
and after coronary intervention is essential in the preven-
tion of thrombosis. Early trials indicated that, in patients
undergoing PCI, aspirin reduced mortality, MI, urgent
revascularization,orstentthrombosisbothwithandwithout
thienopyridines [18, 36–38].
The 2004 ACC/AHA guidelines for coronary artery
bypass graft surgery suggest daily aspirin therapy with 100–
325mg started within 24 hours after surgery [39]. The 2005
ACC/AHA guidelines for percutaneous coronary interven-
tion recommend 75–325mg of aspirin before the PCI pro-
cedure is performed in patients already taking daily chronic
aspirin therapy, and 300–325mg of aspirin at least 2 hours
and preferably 24 hours before the PCI procedure is per-
formed in patients not already taking daily chronic aspirin
therapy [40]. After the PCI procedure, in patients with nei-
ther aspirin resistance, allergy, nor increased risk of bleeding,
aspirin 162–325mg daily should be given for at least 1
month after BMS implantation, 3 months after sirolimus-
eluting stent implantation, and 6 months after paclitaxel-
eluting stent implantation, after which daily chronic aspirin
use should be continued indeﬁnitely at a dose of 75 to
162mg [40]. All of these recommendations belong to class
I (evidence supports that treatment is useful and eﬀective).
4.4. Secondary Prevention for Stroke and Transient Ischemic
Attack. The previous meta-analysis by the ATT Collabora-
tion involved 18270 patients with a history of stroke or
transientischaemicattackin21trials[17].Theresultshowed
that antiplatelet therapy (mainly aspirin alone) for a mean
duration of 29 months can signiﬁcantly reduce the rate of
major vascular events by 22%. Treating 1000 patients with
a history of cerebrovascular disease for this duration will
prevent about 36 vascular events, mostly nonfatal stroke
recurrence (25 fewer per 1000 treated), and some nonfatal
myocardial infarction (5 fewer per 1000).
4.5. Secondary Prevention for Atrial Fibrillation. The pres-
enceofatrialﬁbrillation(AF)givesrisetothedevelopmentof
atrial thrombus and consequently increases the risk of stroke
among elderly people. Vitamin K antagonists, most notable
among which is warfarin, signiﬁcantly reduce the risk of
stroke by almost two-thirds compared to placebo. Owing
to the diﬃculties with using warfarin of its requirement for
frequent monitoring of the INR and increased hemorrhagic
risk with increased duration of therapy, aspirin has been
considered a potential alternate [41–43].
Most of the evidence about the eﬀects of aspirin therapy
among patients with atrial ﬁbrillation was provided by the
European atrial ﬁbrillation trial [44]. High-risk patients
with a previous stroke or transient ischemic attack were
randomized to aspirin or placebo (or oral anticoagulant,
if eligible) in this trial. It was indicated that aspirin is a
safe, though less eﬀective, alternative when anticoagulation
is contraindicated. Aspirin prevents 40 vascular events for4 Thrombosis
every 1,000 treated patients. The previous meta-analysis by
the ATT Collaboration [17] included 2770 patients with
atrialﬁbrillationinfourtrialsandfoundthattherewasapro-
portional reduction of 24% (9%) in serious vascular events.
In patients with “lone AF,” who are under 65 years of
age, not hypertensive, without evidence of cardiovascular
disease and who have normal echocardiograms, the baseline
stroke risk of this cohort is relatively low (approximately
0.5%/year). In this situation, aspirin alone is considered by
m o s te x p e r t st ob ea d e q u a t e[ 41–43].
5. PrimaryPrevention
For primary prevention, the balance between beneﬁts and
risks of aspirin use is less clear because the absolute beneﬁts
of aspirin are generally lower than those in secondary
prevention. Current guidelines largely ignore any diﬀerences
in bleeding risk and recommend that aspirin be used widely
for primary prevention in those at moderately raised risk
of coronary heart disease. It has also been suggested that,
since age is a major determinant of the risk of coronary heart
disease, daily aspirin should be started in all people above a
speciﬁc age, either alone or in combination with other drugs.
To date, six completed randomized trials have eval-
uated the beneﬁts and risks of low-dose aspirin for the
primary prevention of cardiovascular disease. The British
Male Doctors’ Trial (BDT) [45] of 5139 male physicians
and the US Physicians’ Health Study (PHS) [26] of 22071
healthy male were completed during the late 1980s. The
Thrombosis Prevention Trial (TPT) [46] of 5085 men and
the Hypertension Optimal Treatment (HOT) [47]t r i a lo f
18790 (47% women) patients were completed in 1998. The
Primary Prevention Project (PPP) [48] study of 4495 (58%
women) patients and the Women’s Health Study (WHS)
[49] of 39876 healthy females were completed in the 2000s.
In all these trials patients were randomized to aspirin and
had follow-up durations ranging from 3.6 to 10.1 years.
The PHS and BDT used aspirin regimens of 325mg every
other day and 500mg/day, respectively, whereas the TPT and
HOT used 75mg/day of aspirin and the PPP and WHS used
100mg/day of enteric-coated aspirin.
The Antithrombotic Trialists’ (ATT) Collaboration
undertook a meta-analysis in the 6 previous trials and found
that, in the primary prevention trials, aspirin use yielded
a 12% proportional reduction in serious vascular events
(0.51% aspirin versus 0.57% control per year, P = 0.0001),
due mainly to about 20% reduction in nonfatal myocardial
infarction (0.18% versus 0.23% per year, P<0.0001) [23].
The net eﬀect on stroke was not signiﬁcant (0.20% versus
0.21% per year, P = 0.4: haemorrhagic stroke 0.04% versus
0.03%, P = 0.05; other strokes 0.16% versus 0.18% per year,
P = 0.08). Vascular mortality did not diﬀer signiﬁcantly
(0.19%versus0.19%peryear,P = 0.7).Aspirinuseincreased
major gastrointestinal and extracranial bleeds (0.10% versus
0.07% per year, P<0.0001), and the main risk factors for
coronary disease were also risk factors for bleeding.
To better understand the impact of sex on the response
to aspirin, Berger and colleagues conducted a meta-analysis
on the sex-speciﬁc beneﬁts of aspirin in 51342 women and
44114 men enrolled in the 6 previous prevention trials [50].
The results demonstrate that aspirin therapy is associated
with a signiﬁcant reduction in the risk of cardiovascular
events in both sexes. However, the speciﬁc types of beneﬁt
diﬀer in important ways between women and men. Aspirin
use in women was associated with statistically signiﬁcant
reductions in cardiovascular events (odds ratio [OR], 0.88
[CI, 0.79 to 0.99]) and ischemic strokes (OR, 0.76 [CI, 0.63
to 0.93]); no statistically signiﬁcant beneﬁt was found in the
reduction of myocardial infarctions or cardiovascular mor-
tality. In men, aspirin use was associated with a statistically
signiﬁcant reduction in cardiovascular events (OR, 0.86 [CI,
0.78 to 0.94]) and myocardial infarctions (OR, 0.68 [CI, 0.54
to 0.86]); no statistically signiﬁcant beneﬁt was found in the
reduction of ischemic strokes or cardiovascular mortality.
Total mortality was not signiﬁcantly reduced by aspirin use
in men or women.
In summary, consistent evidence from randomized clin-
ical trials indicates that aspirin use reduces the risk for CVD
events in adults without a history of CVD. For primary
prevention of cardiovascular disease, aspirin therapy signif-
icantly reduced the risk of the composite of cardiovascular
events primarily by reducing the risk of ischemic stroke
with no signiﬁcant eﬀect on the risk of MI in women and
predominantly by reducing the risk of MI with no signiﬁcant
eﬀect on the risk of stroke in men.
6.AdverseEffects
Aspirin prevents thrombotic events by inhibiting prostagl-
andin synthesis, which also leads to adverse side eﬀects,
mainly including upper-gastrointestinal (GI) toxicity, extra-
cranial and intracranial haemorrhage [51–53].
Aspirin-induced GI toxicity detected in randomized
clinical trials, including nausea, heartburn, and epigastric
pain, appears to be dose related in the range of 30 to
1,300mg/d.Theprinciplemechanismisduetotheinhibition
of COX-1-dependent prostaglandin E2 (PGE2) synthesis by
aspirin, while PGE2 inhibits acid secretion in gastric mucosa
and increases mucous formation. Buﬀered and enteric-
coated aspirin preparations developed to attenuate local
gastric erosion and minimize this side eﬀect [51].
The overall risk of major extracranial and intracranial
hemorrhage associated with antiplatelet drugs is diﬃcult
to assess in individual trials because their incidence is low
[52, 53]. In the overview of the ATT Collaboration [17], the
overall proportional increase in risk of a major extracranial
hemorrhage with aspirin therapy was about one-half (odds
ratio [OR], 1.6; 95% CI, 1.4 to 1.8). After allowing for
noncompliance in the trials, they are compatible with the
2- to 2.5-fold excess observed in case-control studies. The
overall absolute excess of intracranial hemorrhage due to
aspirin therapy was <1 per 1000 patients per year in high-
risk trials, with somewhat higher risks in patients with
cerebrovascular disease.
Moreover, chronic large dose of aspirin use may reduce
renal blood ﬂow and glomerular ﬁltration and impair renal
function due to the inhibition of COX-2-dependent PGI2,
which support renal perfusion, diminish vascular resistance,Thrombosis 5
and facilitate natriuresis [54]. This side eﬀect often occurs
at high aspirin doses and most frequently in elderly patients
and those with established renal disease.
Furthermore, high-dose aspirin may also attenuate the
beneﬁt of angiotensin-converting enzyme (ACE) inhibitors
in hypertensive and congestive heart failure patients because
aspirinmayattenuatethesynthesisofPGE3andPGI2,which
is promoted by ACE inhibitors [55–57].
In summary, aspirin is eﬀective for the prevention of
thrombosis because of the inhibition of TXA2-dependent
platelet function, which is also associated with excess bleed-
ing. Assessing the net eﬀect requires an estimation of the
absolute thrombotic versus hemorrhagic risk of the individ-
ual patient.
7.AspirinResistance
Aspirin resistance has been used to describe the inability
of aspirin to protect individuals from thrombotic compli-
cations, cause a prolongation of the bleeding time, reduce
TXA2 production, or produce typical eﬀect in vitro tests
of platelet function [58, 59]. However, a standard, clear,
and distinct deﬁnition of aspirin resistance has not been
established yet.
The rate of aspirin resistance is widely variable, ranging
from 5 to 60% of the population aﬀected by cardiovascular
and cerebrovascular diseases in diﬀerent studies [58–60]. It
is diﬃcult to know the exact prevalence of aspirin resistance
from these studies because of variabilities in deﬁnitions for
aspirin resistance, variabilities in testing and measurement
between studies, small sample size of the studies, and diﬀer-
ent populations used in the studies. Many laboratory tests
are currently used to investigate platelet activity and platelet
response to aspirin, such as measurements of thromboxane
biosynthesis, platelet aggregation, and platelet activation,
bleeding time.
The potential mechanisms of aspirin resistance include
enhanced platelet turnover, genetic polymorphisms of COX-
1 and other genes involved in thromboxane biosynthesis,
upregulation of nonplatelet sources of thromboxane biosyn-
thesis, and the interactions of other drugs [58, 61, 62].
Because of a series of adverse cardiovascular events asso-
ciated with aspirin resistance, once aspirin resistance is con-
ﬁrmed by laboratory measures, recommendations for alter-
ation of therapy (dose change or additional antiplatelet
agent) and followup are needed for meaningful clinical out-
comes.
8. Conclusions
Aspirin remains the cornerstone of antiplatelet therapy in
patients with cardiovascular disease. It decreases mortality
and recurrence of cardiovascular events when used as acute
therapy following acute coronary syndrome, thrombotic
stroke, and Kawasaki’s disease. It is also of proven beneﬁt
in secondary prevention among a wide range of patients,
including those with acute coronary syndrome, stable
angina, revascularization, stroke, TIA, and atrial ﬁbrillation.
In primary prevention, aspirin therapy appears to reduce the
risk for CVD events in adults without a history of CVD with
sex speciﬁc beneﬁts. Aspirin may be considered for patients
with a high risk of future CVD, but the beneﬁts must be
weighed against the possibility of side eﬀects. The concept
of resistance to aspirin is still an emerging and important
clinical question requiring further study.
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